Cambridge Trust’s Neurocrine Biosciences NBIX Stock Holding History

Cambridge Trust’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-29	Closed	-$3K	–	797
2022 Q4	$3K	Buy	+29	New	+$3.4K	﹤0.01%	750

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Cambridge Trust's NBIX Position: Q1 2023 in Review

Cambridge Trust sold out of Neurocrine Biosciences (NBIX) in Q1 2023, closing a stake of 29 shares — an estimated $3K sold.

Cambridge Trust first reported a position in NBIX in Q4 2022 and held it in 1 quarter. The position peaked at $3K in Q4 2022. 486 funds tracked by Wall St. Rank hold NBIX as of Q1 2023.

Cambridge Trust reported no remaining Neurocrine Biosciences position as of Q1 2023 after selling out during the quarter.
Cambridge Trust sold 29 Neurocrine Biosciences shares in Q1 2023, an estimated $3K.
Cambridge Trust first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 1 quarter.
Cambridge Trust's Neurocrine Biosciences position peaked at $3K in Q4 2022.
486 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2023.

Based on Cambridge Trust's 13F filing for Q1 2023, filed 12 May 2023.